Market Movers

The Cooper Companies, Inc.’s Stock Price Soars to $81.40, Marking a Robust 5.67% Increase

By December 6, 2025 No Comments

The Cooper Companies, Inc. (COO)

81.40 USD +4.37 (+5.67%) Volume: 9.32M

The Cooper Companies, Inc.’s stock price climbs to 81.40 USD, witnessing a significant surge of +5.67% in the current trading session with a substantial trading volume of 9.32M, despite a year-to-date decline of -10.79%, demonstrating a volatile yet intriguing performance.


Latest developments on The Cooper Companies, Inc.

Cooper Companies (COO) saw a surge in its stock price today after announcing a strategic review and appointing a new board chair. The positive sentiment was further fueled by strong Q4 earnings that surpassed estimates. Analysts at Mizuho raised the stock price target to $100 from $85, reflecting confidence in the company’s performance. With the anticipation of higher Q4 earnings, investors are closely watching Cooper Companies as it continues to make strategic moves to drive growth and shareholder value.


A look at The Cooper Companies, Inc. Smart Scores

FactorScoreMagnitude
Value3
Dividend1
Growth3
Resilience2
Momentum4
OVERALL SMART SCORE2.6

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Looking ahead, the long-term outlook for Cooper Cos is positive, with a strong momentum score of 4 indicating good potential for future growth. The company also scores well in terms of value and growth, with scores of 3 in both categories. However, its resilience score of 2 suggests some vulnerability to market fluctuations. Additionally, Cooper Cos scores low in the dividend category, with a score of 1, which may be a concern for investors looking for steady income.

The Cooper Companies, Inc. is a healthcare company that focuses on developing, manufacturing, and marketing specialty healthcare products. Its product range includes contact lenses for the vision care market, as well as diagnostic products, surgical instruments, and accessories for gynecologists and obstetricians. With a mixed bag of scores in various categories, investors may want to closely monitor the company’s performance and market conditions to make informed decisions about its long-term prospects.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars